It is hypothesised that targeting H4R, which is implicated in inflammatory processes, could offer therapeutic advantages for controlling the symptoms of IBS and other inflammatory gastrointestinal disorders [30]. The gene discussed is HRH4; the disease is irritable bowel syndrome.